Hematopoietic and lymphoid system neoplasm
MONDO:0002334Neoplasms of the hematopoietic system, including hematopoietic cell neoplasms (e.g. leukemias, lymphomas) and non-hematopoietic cell neoplasms that can affect the hematopoietic system (e.g. lymph node and splenic sarcomas). --2003
Also known as: haematopoietic neoplasm, haematopoietic neoplasm (morphologic abnormality), hematologic neoplasm, hematopoietic neoplasm, hematopoietic neoplasm (morphologic abnormality), blood neoplasm (disease), blood tumor, blood tumour
7597 clinical trials for this condition and its sub-types, 692 tagged with Hematopoietic and lymphoid system neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematopoietic and lymphoid system neoplasm
-
Hematopoietic and lymphoid cell neoplasm 484 trials · 5,928 incl. sub-types
8 sub-types
- Lymphoid neoplasm 11 trials · 4,263 incl. sub-types Sub-types →
- Myeloid neoplasm 48 trials · 2,703 incl. sub-types Sub-types →
- Leukemia 360 trials · 2,561 incl. sub-types Sub-types →
- Refractory hematologic cancer 62 trials · 310 incl. sub-types Sub-types →
- Central nervous system hematopoietic neoplasm 0 trials · 107 incl. sub-types Sub-types →
- Histiocytic and dendritic cell neoplasm 9 trials · 98 incl. sub-types Sub-types →
- Myelodysplastic syndrome with excess blasts 71 trials · 83 incl. sub-types Sub-types →
- Myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 0 trials · 4 incl. sub-types Sub-types →
-
Lymphoid hemopathy 0 trials · 4,275 incl. sub-types
4 sub-types
- Lymphoma 606 trials · 4,243 incl. sub-types Sub-types →
- Histiocytic and dendritic cell neoplasm 9 trials · 98 incl. sub-types Sub-types →
- Persistent polyclonal B-cell lymphocytosis 5 trials
- Immunodeficiency-associated lymphoproliferative disease 1 trial Sub-types →
-
Myeloid hemopathy 0 trials · 1,762 incl. sub-types
4 sub-types
- Myeloproliferative neoplasm 165 trials · 1,630 incl. sub-types Sub-types →
- Myelodysplastic syndrome 653 trials · 671 incl. sub-types Sub-types →
- Myelodysplastic/myeloproliferative disease 31 trials · 205 incl. sub-types Sub-types →
- Myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 0 trials · 4 incl. sub-types Sub-types →
-
Bone marrow neoplasm 3 trials · 1,631 incl. sub-types
1 sub-type
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
-
Thymus neoplasm 5 trials · 240 incl. sub-types
4 sub-types
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Thymic epithelial neoplasm 14 trials · 56 incl. sub-types Sub-types →
- Thymic neuroendocrine tumor 3 trials · 6 incl. sub-types Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
-
Spleen neoplasm 0 trials · 232 incl. sub-types
3 sub-types
- Marginal zone lymphoma 213 trials · 232 incl. sub-types Sub-types →
- Spleen cancer 0 trials · 2 incl. sub-types Sub-types →
- Benign neoplasm of spleen 0 trials Sub-types →
-
Lymph node neoplasm 5 trials · 59 incl. sub-types
3 sub-types
- Lymph node cancer 1 trial · 55 incl. sub-types Sub-types →
- Benign neoplasm of lymph node 0 trials
- Lymph node palisaded myofibroblastoma 0 trials
-
Cavernous hemangioma 1 trial
7 sub-types
- Cavernous hemangioma of colon 0 trials
- Cavernous hemangioma of face 0 trials Sub-types →
- Cavernous hemangioma of orbit 0 trials
- Dermal unilateral segmental cavernous angioma 0 trials
- Giant hemangioma 0 trials
- Intracranial cavernous angioma 0 trials
- Liver cavernous hemangioma 0 trials
Most studied deeper sub-types
-
Can a daily pill shrink the spleen in myelofibrosis?
Disease control Stopped earlyThis phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on viruses in cancer patients
Disease control Stopped earlyThis early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental lung inflammation treatment trial shuts down after just one patient
Disease control Stopped earlyThis phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for myelofibrosis patients who stop responding to standard therapy
Disease control Stopped earlyThis phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…
Phase 1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising GVHD prevention trial halted early – too few patients to draw conclusions
Disease control Stopped earlyThis phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control Stopped earlyThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control Stopped earlyThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients
Disease control Stopped earlyThis study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic t…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can extra care after transplant help older patients live better?
Disease control Stopped earlyThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase 2/3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer Patients' COVID-19 trial halted after just 4 volunteers
Disease control Stopped earlyThis early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Bleeding breakthrough fizzles: fibrinogen trial for chemo patients halted after just one patient
Disease control Stopped earlyThis study tested a single injection of fibrinogen concentrate followed by a platelet transfusion in blood cancer patients with severe bleeding who did not respond to standard platelet transfusions. The goal was to see if it improved blood clotting. However, the trial was termina…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug BR108 tested in blood cancer patients – early results uncertain
Disease control Stopped earlyThis early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New transplant method shows promise for tough blood cancers
Disease control Stopped earlyThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control Stopped earlyThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo for tough leukemia hits roadblock: trial stopped early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control Stopped earlyThis early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for kids after transplant: study tests safer GVHD prevention
Disease control Stopped earlyThis study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Radiation after failed CAR t: tiny study halted early
Disease control Stopped earlyThis pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a PET scan spot silent heart danger from cancer drugs?
Diagnosis Stopped earlyThis pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Can a smartphone app help cancer patients fight depression?
Symptom relief Stopped earlyThis study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate …
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New program aims to help parents with advanced cancer support their kids
Symptom relief Stopped earlyThis study tested two educational programs for parents with late-stage cancer who have children aged 5 to 17. The programs were designed to improve parent-child relationships and boost parents' confidence in talking about cancer with their kids. Researchers hoped to reduce anxiet…
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New platform seeks to break down barriers for underserved cancer patients in clinical trials
Knowledge-focused Stopped earlyThis study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized p…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Fitness trackers vs. Doctor's eye: which better gauges cancer Patients' mobility?
Knowledge-focused Stopped earlyThis study tested whether consumer movement trackers could provide a more precise measure of cancer patients' physical abilities than the standard ECOG score, which relies on a doctor's observation. Researchers enrolled 41 cancer patients and used a Kinect device to record their …
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Liver impairment study for cancer drug tazemetostat halted early
Knowledge-focused Stopped earlyThis study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …
Phase 1 • Sponsor: Epizyme, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Siblings' voices: what kids want to know when a brother or sister has cancer
Knowledge-focused Stopped earlyThis study looked at how healthy brothers and sisters of children with blood cancer felt about the information they got about the disease. Researchers interviewed 7 children aged 6 to 12 to understand their satisfaction and what they thought about the illness. The goal was to imp…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC